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Abstract: Diabetes mellitus is characterized by chronic hyperglycemia caused by a deficiency in insulin action, insu-
lin secretion or both. Type 1 diabetes is classified as the destruction of beta cells leading to a deficiency in insulin 
production. Type1 diabetes accounts for 5-10% of patients with diabetes and most commonly is caused by the 
autoimmune destruction of the beta cells in the pancreas. The adaptive immune system is composed of antigen 
specific T and B lymphocytes which play a central role in protecting the human body from infectious pathogens but 
occasionally autoreactive T and B cells can escape immune tolerance, become activated and induce autoimmune 
diseases. Naïve T cells require two distinct signals one delivered via the antigen receptor and the second through 
the costimulatory receptor CD28 that leads to the induction of IL-2 gene transcription. IL-2 is an important T cell 
growth factor that can influence both immunity and tolerance. Given its pivotal role it is not surprising that the 
immune system places strict regulation over Il2 gene transcription that is controlled by a number of E3 ubiquitin 
ligases that modulate TCR and CD28 signaling. This review will examine how different E3 ligases function to control 
T effector cell differentiation and how studies in gene knockout animal models has been crucial in understanding 
how these proteins function in vivo to regulate immune tolerance in the peripheral circulation.
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Introduction
Diabetes mellitus is a significant problem 
throughout the world that is caused by chronic 
hyperglycaemia and without treatment can 
lead to severe life threatening complications 
caused by dysfunction and/or failure of various 
organs including eye, kidney, nerves, heart and 
blood vessels. Genetic and environmental fac-
tors contribute to the etiology of diabetes. Type 
1 diabetes (T1D) accounts for 5-10% of patients 
with diabetes and occurs most commonly in 
childhood and adolescence [1]. The disease is 
caused by the autoimmune destruction of the 
beta cells within the islets of Langerhans in the 
pancreas due to activation of islet reactive T 
and B cells. Pancreatic beta cells are the sole 
source of insulin production in the body and fol-
lowing injury the regenerative potential of the 
beta cell is limited. This is because beta cells 
are largely senescent due to the expression of 
cell cycle inhibitors such as p27kip1 and p16Ink4a 
[2-4]. Also recent studies have identified that 
there is no contribution to the adult beta cell 
mass by specialized progenitors or stem cells 
[5]. Instead adult beta cells are the product of 
self-duplication [5, 6]. Therefore the partial 
growth ability of the beta cell is insufficient to 
permit recovery from cell loss as experienced in 
overt T1D. As a result the loss of beta cell mass 
leads to a chronic loss of insulin production and 
dysregulation of blood glucose homeostasis 
that eventually leads to the clinical symptoms 
of diabetes.
Patients with T1D can secrete anti-insulin anti-
bodies due to activation of autoreactive B cells, 
while islet reactive CD4+ and CD8+ T cells have 
been identified in the peripheral blood of 
patients. The main target antigens of diabeto-
genic T cells include islet derived proteins such 
as insulin, GAD65 and insulinoma associated 
protein A2 (IA2) [7]. The activation of both T and 
B lymphocytes in T1D patients indicates that 
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the disease is caused by a generalized break-
down of immune tolerance whereby activation 
of islet reactive CD4+ T cells can lead to cog-
nate activation of islet specific B cells and the 
generation of autoantibodies directed to islet 
specific proteins. Animal models have been 
particularly useful in helping to define the cel-
lular and molecular basis of disease pathology 
associated with T1D and these have contribut-
ed to a better understanding of the disease in 
humans [8]. 
Immune tolerance to self antigens is estab-
lished through central or peripheral mecha-
nisms. Central tolerance occurs during T cell 
development in the thymus through deletion of 
self reactive T cells that express a TCR with 
high affinity for self antigens. This process is 
directed by the presentation of antigen by med-
ullary epithelial cells that express the autoim-
mune regulator gene (AIRE) that directs ectopic 
expression of tissue specific antigens in the 
thymus [9-11]. In the absence of Aire central 
tolerance is severely compromised and autore-
active T cells can escape deletion and enter the 
periphery. Patients with the rare autoimmune 
polyendocrinopathy syndrome 1 (APS-1) have 
mutations in the Aire gene that predisposes to 
organ specific autoimmunity including thyroid-
itis and diabetes [12, 13].  The efficiency of 
clonal deletion is not absolute and so even in 
healthy individuals a small proportion of auto-
reactive T cells can escape thymic deletion and 
enter the peripheral circulation. The immune 
system must control the activation of these 
cells to prevent autoimmunity and this is 
achieved through a combination of dominant 
(extrinsic) and recessive (cell intrinsic) 
mechanisms. 
Dominant tolerance is mediated primarily by 
the suppressive effects of regulatory T cells in 
particular the naturally occurring CD4+ Foxp3+ 
Treg (nTregs) cells that arise during T cell devel-
opment in the thymus or by inducible Tregs 
(iTregs) that arise in the peripheral circulation in 
response to tolerance inducing regimes (e.g. 
mucosal delivery of antigen) [14, 15]. Recessive 
tolerance is regulated by cell intrinsic mecha-
nisms that control the fate of autoreactive T 
cells especially in the periphery. The CD95 
(Fas)/ CD95L (FasL) pathway is a member of 
the TNF receptor family and plays a critical role 
in regulating programmed cell death of activat-
ed T cells [16]. Other inhibitory pathways 
include PD-1/PD-1L and CTLA-4 which are 
important for preventing cellular activation and 
proliferation [17, 18]. Growth factors such as 
interleukin 2 (IL-2) and transforming growth 
factor–β (TGF-β) have important roles in regu-
lating T cell proliferation and for maintaining 
homeostasis of Treg cells in the peripheral cir-
culation [19-21]. Self reactive T cells can under-
go functional inactivation through a process 
referred to as clonal anergy. The development 
of anergy leads to an abortive activation that 
makes cells unresponsive to stimulation 
through the TCR [22, 23]. Several E3 ubiquitin 
ligases are induced in anergic T cells and they 
play a central role in ubiquitinating specific sig-
nalling molecules located downstream of the 
TCR to target them for degradation. 
In this chapter some of the key E3 ligases that 
have specific roles in regulating T cell respons-
es will be examined and how defects in the 
function of these ligases can lead to organ spe-
cific autoimmune diseases.
E3 ubiquitin ligases
Ubiquitin is a 76 amino acid polypeptide that is 
involved in the posttranslational modification 
of proteins [24]. Ubiquitin is added by the 
sequential activity of three enzymes; E1 is an 
activating enzyme, E2 is a conjugating enzyme 
and E3 is a ligase that attaches the ubiquitin 
moiety to the target protein. Proteins can either 
be subject to mono- or poly-ubiquitination [25, 
26]. Ubiquitin molecules are generally linked 
through the lysine (Lys) residue at position 48 
or 63 and a protein can be tagged with a single 
ubiquitin (i.e. monoubiquitinated) or it may be 
tagged with multiple ubiquitins in an elongated 
chain which is referred to as (polyubiquitina-
tion) [27, 28]. Proteins that become tagged with 
multiple ubiquitins on Lys48 are destined for 
degradation in the 26S proteosomal complex. 
In contrast proteins that are monoubiquitinated 
or have the addition of multiubiquitins to lysine 
residues apart from Lys48 can alter protein 
trafficking between subcellular compartments 
or protein function [29]. 
Three families of E3 ligases have been identi-
fied including the really interesting new gene 
(RING) type, homologous to the E6 associated 
protein carboxy terminus (HECT) type and the 
U-box type proteins [24]. The E3 ligases are 
involved in the transfer of the ubiquitin from an 
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appropriate E2 ubiquitin donor to the protein 
substrate. Several RING and HECT type E3 
ligases have been implicated in the regulation 
of immune function and disrupting their func-
tion in vivo can have important consequences 
on the development of autoimmune diseases 
[30]. This outcome highlights that the immune 
system relies on the E3 ligases to restrain the 
autoimmune potential of self-reactive lympho-
cytes. In the following discussion we will focus 
on the role of key E3 ligases such as Cbl-b, Itch, 
Grail and Roquin to illustrate how these mole-
cules control T cell activation.
To achieve complete activation of naïve T cells 
requires the delivery of two discrete signals, 
one transmitted through the TCR and the other 
which is delivered via the costimulatory recep-
tor CD28 in response to binding to its ligands 
CD80/CD86 on the surface of APCs. Both sig-
nals facilitate the recruitment of a number of 
transcription factors (e.g. NF-kB, AP-1, NFAT) to 
the promoter of the Il2 gene locus that lead to 
the de-repression of the Il2 gene, Il2 mRNA 
transcripts become stabilized and are translat-
ed into protein to drive T cell proliferation [31] 
(Figure 1A). IL-2 can act in an autocrine and 
paracrine fashion to drive T cell proliferation 
and to enable effector cell differentiation. 
Therefore it is not surprising that the immune 
system places the regulation of Il2 gene tran-
scription under tight transcriptional control to 
prevent inappropriate activation of naïve T cells 
in the periphery and the possibility of 
autoimmunity. 
Naive T cells that receive only a TCR signal 
undergo an abortive activation that leads to a 
state of immune unresponsiveness termed 
clonal anergy. Clonal anergy was originally 
defined using mouse CD4+ Th cell clones stim-
ulated in the absence of CD28 costimulation 
and human CD4+ T cell clones can also be ren-
dered anergic following stimulation with pep-
Figure 1. Induction of ubiquitin ligases in response to T cell anergy. A: T cells become fully activated in response to 
signals through the TCR and CD28 costimulatory receptor. Intracellular signals are transduced from the TCR and 
CD28 to the nucleus leading to IL-2 gene transcription and the secretion of the cytokine promoting autocrine and 
paracrine growth of T cells, but ubiquitin ligase gene expression is inhibited. B: T cells that receive a signal only 
through the TCR or experience sustained elevated levels of Cai
++ leads to abortive activation and the development 
of T cell anergy. The anergic state is characterized by inhibition of IL-2 gene transcription but increased expression 
of a range of ubiquitin ligase genes.
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tide antigen in the absence of APCs [32-34]. To 
study the molecular and biochemical basis of T 
cell anergy Rao and colleagues cultured T cells 
in the presence of ionomycin to artificially raise 
intracellular calcium levels and this was suffi-
cient to induce a state of anergy [35, 36]. These 
studies revealed that the induction of anergy in 
T cells was an active process that is dependent 
on new protein synthesis and is associated 
with the increased expression of a range of E3 
ubiquitin ligases such as Cbl-b, Itch, Grail and 
Nedd4 and other negative regulators of TCR 
signaling including diacyglycerol kinase, cas-
pase3, Traf6, Ikaros, Egr2, Egr3 and CREM 
(cyclic AMP response element modulator) [37-
43] (Figure 1B). 
Casitas B-lineage lymphoma (Cbl) proteins
The Casitas B-lineage lymphoma (Cbl) family of 
RING type ubiquitin ligases are key negative 
regulators of cell surface growth factor recep-
tor signals [44, 45]. Mammals have three Cbl 
homologues c-Cbl, Cbl-b and Cbl-3 while D-Cbl 
and Sli-1 are the Drosophila melanogaster and 
Caenorhabditis elgans homologous proteins 
respectively [46]. Cbl-3 does not appear to 
have any role in the immune system but c-Cbl 
and Cbl-b are required to modulate TCR signal-
ling. C-cbl is predominantly expressed in the 
thymus and testes [47] while Cbl-b proteins are 
expressed primarily in peripheral T cells [48]. In 
T cells c-Cbl functions to regulate the threshold 
of TCR signalling by forming a complex with 
Zap70 and CD3ζ to promotes CD3ζ ubiquitina-
tion. This leads to down regulation of the TCR/
CD3 complex following ligand binding to pep-
tide/MHC complexes. In the absence of c-Cbl 
thymocytes display high level expression of the 
TCR/CD3 complex at the cell surface that 
appears from the DP stage of development. 
Negative selection of autoreactive thymocytes 
proceeds normally in the thymus of c-Cbl-/- mice 
but positive selection of thymocytes is 
enhanced [49, 50]. There is no evidence of 
spontaneous autoimmunity in c-Cbl-/- mice con-
sistent with the intact negative selection and 
normal Treg cell differentiation [49, 50] Ho, 
Hoyne unpublished observations).
The Cbl-b protein is dispensable for T cell devel-
opment but it does play important roles in TCR 
modulation and the induction and maintenance 
of T cell clonal anergy. Studies by Naramura et 
al showed the combined loss of c-Cbl and Cbl-b 
leads to constitutive expression of TCR/CD3 at 
high levels on thymocytes and these cells are 
resistant to CD3 induced TCR modulation [48]. 
Cbl-b can interact with CrkL adapter protein 
and C3G the guanine nucleotide exchange fac-
tor for Rap1 [51]. The loss of Cbl-b does not 
affect the stability of CrkL but its association 
with C3G that can lead to enhanced expression 
of LFA-1 and clustering of T cells following TCR 
signalling [51]. These results imply that Cbl-b is 
a negative regulator of CrkL-C3G signaling. In 
addition Cbl-b plays a crucial role as a negative 
regulator of CD28 signaling in T cells to vav and 
Rac1 [52] (Figure 2). Target proteins of Cbl-b 
mediated ubiquitination include the p85 sub-
unit of phosphatidyl inositol kinase (PI3K) 
which is activated in response to CD28 signal-
ling [53, 54] and is also required to inhibit phos-
phorylation of PLC-γ1 [55]. As Cblb deficient 
mice are unable to restrain TCR signaling they 
become highly susceptible to develop sponta-
neous autoimmunity and T cells display hyperp-
roliferation in response to TCR signaling and 
secrete IL-2 in the absence of a costimulatory 
signal [48, 52, 56]. However, a recent report by 
St Rose et al showed that Cblb deficient T cells 
were still resistant to anergy induction when 
adoptively transferred to recipient mice 
expressing a neo-self target antigen expressed 
either in soluble form or on mesenchymal tis-
sues [57]. 
Additional evidence for the crucial role Cbl-b 
plays in the regulation of immune tolerance 
came with the identification of the Komeda dia-
betes prone (KDP) rat strain that develops 
spontaneous type 1 diabetes due to a loss of 
function mutation in Cblb [58]. The emergence 
of autoimmune diabetes in the KDP strain 
requires additional susceptibility factors includ-
ing a diabetes-susceptible MHC haplotype that 
leads to selection islet reactive T cells in the 
thymus [58]. Studies with inbred strains of mice 
indicate that Cbl-b on its own is not sufficient to 
cause spontaneous autoimmunity. However, 
diabetes can develop if the frequency of islet 
reactive CD4+ T cells is elevated by transgenic 
expression of a TCR specific for a neoself anti-
gen expressed on islet beta cells. The TCR x 
insHel model is a highly sensitized mouse strain 
that has been used extensively to study defects 
in negative selection and defective nTreg differ-
entiation on the development of islet autoim-
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munity [11, 59-61]. The Cblb deficiency does 
not affect negative selection of autoreactive T 
cells in the TCR x insHel model, nor the differ-
entiation of nTregs that develop in the thymus 
but ~ 80% of Clbb-/- TCR x insHel double trans-
genic mice develop type 1 diabetes with exten-
sive lymphocyte infiltration and immune medi-
ated destruction of pancreatic beta cells [62]. 
However the studies identified a paradox 
whereby the numbers of islet reactive T cells in 
the peripheral circulation of Clbb-/- TCR x insHel 
double transgenic mice were not dissimilar to 
that of wild type TCR x insHel animals indicating 
that the immune system was able to control the 
homeostasis of naïve autoreactive T cells. 
However the islet reactive T cells from Clbb-/- 
TCR x insHel double transgenic mice proliferat-
ed extensively and secreted effector cytokines 
following restimulation with HEL antigen in vitro 
indicating a breakdown in T cell anergy com-
pared to wild type cells from TCR x insHel which 
remained unresponsive to the Hel stimulation.
Grail and Itch and their role in T cell anergy
Grail is a RING type E3 ubiquitin ligase that con-
trols autoimmunity in mice that is separate to 
the function of Cbl-b described above. Grail is 
encoded by the Rfn128 gene was originally 
identified through a differential display PCR 
screen of anergic CD4+ T cells. Its expression is 
strongly induced following the induction of 
anergy in CD4+ T cells and functions to inhibit 
IL-2 production following TCR ligation [63]. Grail 
controls TCR signalling in T cells by selectively 
inhibiting RhoGTPase activity but it does not 
affect Ras activation or MAPK signaling [64] 
(Figure 2). Rfn128 deficient mice are more sus-
ceptible to autoimmune diseases and naïve T 
cells from the gene knockout mice hyperprolif-
erate in vitro following TCR stimulation in the 
absence of costimulation which is similar to the 
phenotype observed for Clbb-/- T cells [65]. Grail 
also appears to have an important role in Treg 
cell function as the increased susceptibility to 
Figure 2. E3 ubiquitin ligases play a crucial role in regulating TCR signalling. The E3 ligases c-Cbl and Cbl-b can 
ubiquitinate the TCR leading its internalization and targeting to endosome. The Cbl proteins also play an important 
role in attenuating CrkL/C3G signalling. Cbl-b, Itch and Grail can also ubiquitinate intracellular signalling proteins 
to dampen signalling into the nucleus. The ubiquitinated proteins are targeted to endosomes and these form lyso-
somes that result in the destruction of the proteins. 
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autoimmunity of Rfn128 deficient mice is due 
to a lack of suppressive activity of Tregs [65].
The HECT (Homologous to the E6 associated 
protein carboxy terminus) type E3 ubiquitin 
ligases also play a role in the regulation of T cell 
anergy [35, 66]. The Itchy mouse strain devel-
ops a spontaneous and lethal systemic proin-
flammatory disease consistent with a failure of 
peripheral tolerance. The disease is associated 
with an expansion of Th2 type T cells that trig-
ger a chronic pulmonary interstitial inflamma-
tion with elevated levels of IgE antibodies that 
results in skin irritation and the mice itch inces-
santly [53, 67]. A mutation in the Itch gene was 
responsible for the disease manifestation in 
these mice [67]. As an E3 ligase itch promotes 
ubiquitination of target proteins including JunB, 
Cbl-b, PKC-q and Bcl-10 [35, 53, 68]. It was 
originally shown that Itch targets JunB for deg-
radation which is a transcription factor required 
for the formation of the AP1 transcription factor 
that regulates Il-2 gene transcription. In 
response to activation of calcium/calcineurin 
signaling in T cells Itch targets the degradation 
of both PLC-γ1 and PKC-θ to dampen TCR sig-
nalling because reduced levels of these two 
proteins reduces the longevity of the immune 
synapse formed between the T cell and APC 
[35] (Figure 2). 
Additional roles for Cbl-b and Itch in the con-
trol of inducible Treg cell function
Thymus derived CD4+ T regulatory cells or natu-
ral Tregs (nTreg cells) are essential for control-
ling autoimmune and inflammatory responses. 
nTreg cells represent a specialized subpopula-
tion of T cells that arise in the thymus during 
CD4+ TCRaβ+ cell differentiation through 
expression of the fork head winged helix tran-
scription factor Foxp3 [15]. The expression of 
Foxp3 leads to a program of gene expression 
that directs to Treg differentiation and there is 
a requirement for sustained Foxp3 expression 
to maintain their immunoregulatory function in 
the periphery [69-71]. The importance of CD4+ 
Foxp3+ Tregs in the maintenance of immune 
tolerance is supported by the lethal multiorgan 
autoimmunity that occurs in both humans and 
mice due to a failure in Treg cell differentiation 
[72, 73]. The selection of Treg cells in the thy-
mus requires strong TCR: MHC interactions [74] 
and co-stimulatory signals from CD28 [75-77].
Mature nTreg cells migrate from the thymus 
and enter the peripheral T cell pool where their 
homeostasis is controlled by distinct mecha-
nisms compared to naive and memory T cells. 
IL-2, a member of γc cytokine family, is critical 
for the long term survival of Treg cells in the 
periphery [78]. A second subset of cells with 
immunosuppressive functions have been char-
acterized. These are known as inducible Tregs 
(iTregs) and are derived in the periphery from 
naïve CD4+ CD25- T cells [79]. iTreg cells can 
be readily isolated in vitro by culturing naïve 
CD4+ T cells in the presence of TGF-β (and 
IL-10, IL-2) and they begin to express Foxp3 and 
they differentiate as a Treg cells [80-83] . The 
iTregs function in an equivalent manner in 
being able to suppress responses of other T 
cells whether in vitro or in vivo. The mechanism 
of suppression by Tregs is mediated by secre-
tion of inhibitory cytokines (e.g. IL10, IL-35 or 
TGF-β) and/or cell-cell contact [15]. 
Naïve CD4+ CD25- T cells from Cblb-/- and Itch-
/- mice show poor induction of Foxp3 expres-
sion and the iTregs induced are functionally 
less suppressive in co-culture experiments with 
wild type naïve T cells [62, 66, 84, 85]. The 
mechanism by which Cbl-b and Itch regulate 
iTreg cell differentiation in response to TGF-b 
stimulation is quite distinct. An important tar-
get of Itch in naïve CD4+T cells is the TGF-b 
induced early gene (TIEG1, Klf10) product [85]. 
Studies by Liu and colleagues have revealed 
that Itch and TIEG1 can bind to the promoter of 
Foxp3 to allow transactivation [85]. When wild 
type naïve CD4+ T cells are cultured in the pres-
ence of TGF-b T cell proliferation is inhibited 
and Itch and TIEG1 lead to the induction of 
Foxp3 directing iTreg cell differentiation. In the 
absence of Itch, naïve CD4+ T cells are resis-
tant to the inhibitory effects of TGF-β, and 
TIEG1 is unable to promote efficient expression 
of Foxp3 and preventing iTreg cell differentia-
tion [85]. Similarly, CD4+ TIEG1-/- T cells are 
resistant to the effects of TGF-b in vitro and are 
unable to induce Foxp3 expression [85]. Taken 
together these studies have identified an 
important role between the E3 ubiquitin ligase 
Itch and TIEG1 in the differentiation of iTreg 
cells in vivo. 
As discussed above, Cbl-b plays an important 
role in modulating the strength of TCR signaling 
in T cells. Signaling downstream of the TCR and 
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growth factor receptors (e.g. IL-2R) leads to 
activation of PI3 kinase (PI3K), the serine thre-
onine kinase AKT and mammalian target of 
rapamycin (mTOR) to stimulate proliferation 
and to help activated T cells to avoid the induc-
tion of anergy [86, 87]. Activation of AKT 
increases the activity of mTOR which in turn 
phosphorylates the Foxo transcription factors 
(e.g. Foxo 1 and Foxo 3a) which leads to their 
nuclear export and subsequent degradation 
[88]. The immunosuppressive drug Rapamycin 
is an inhibitor of mTOR, and treatment of naïve 
T cells with rapamycin can induce T cell anergy 
in vitro [89]. The induction of anergy requires 
the complete inhibition of mTOR activity and 
there is heightened activation of the calcineu-
rin/NFAT pathway [23]. It is now apparent that 
the induction of Foxp3 expression in naïve T 
cells to induce iTreg differentiation in response 
to TGF-b treatment requires proteins that block 
PI3K activity such as Cbl-b and PTEN [90, 91]. 
mTOR deficient CD4+ T cells are hypersensitive 
to TGF-β treatment and switch on Foxp3. Two 
recent studies have identified that regulation of 
the Foxo1 and Foxo3a transcription factors is 
essential for TGF-β mediated iTreg cell differen-
tiation [84, 92, 93]. Cblb is required in anergic 
CD4+T cells to inhibit PI3K signaling by target-
ing the p85 subunit for degradation [35, 55]. By 
disrupting PI3K signaling, this prevents AKT 
activation and the Foxo1 and Foxo3a transcrip-
tion factors remain de-phosphorylated and can 
induce expression of Foxp3 in response to 
TGF-b signaling. However in the absence of Cbl-
b, PI3K/AKT signaling in naïve T cells is not 
inhibited, and Foxo1 and Foxo3a become phos-
Figure 3. Role of ubiquitin ligases in the induction of Foxp3 gene expression in iTreg cells. Naïve CD4+ T cells can 
be induced to differentiate into iTreg cells through induction of the foxp3 gene expression. TGF-b signalling leads to 
phosphorylation of SMAD2/3 which associates with SMAD4 and the complex translocates to the nucleus where it 
leads to induction of the TIEG1 gene. The TIEG1 protein can be mono-ubiquitinated by the HECT ligase Itch which 
promotes its migration to the nucleus where it can bind to the Foxp3 promoter in association with SMAD complex 
leading to induction of Foxp3 expression. The expression of Foxp3 triggers the Treg differentiation program and 
leads to control of immune responses. Cbl-b ubiquitinates PI3K targeting it for degradation and this prevents activa-
tion of the serine threonine kinase AKT which is required for phosphorylation of the Foxo transcription factors. In the 
absence of phosphorylation the Foxo transcription factors translocate to the nucleus where they bind to the Foxp3 
promoter to induce gene expression.  B: In the absence of TGFbR signalling the Cbl-b ubiquitin ligase ubiquitinates 
the SMAD2/3 complex which targets it for degradation and thus prevents Foxp3 expression.
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phorylated and are degraded and are not avail-
able to induce Foxp3 expression resulting in 
impaired iTreg differentiation [84, 94] (Figure 
3). 
Roquin constrains autoimmunity by regulating 
Tfh cell functions in vivo
Roquin is a relatively new member of the RING 
finger protein family with E3 ligase activity that 
is encoded by the Rc3h1 gene [61]. The Roquin 
protein has emerged to be a key regulator of T 
follicular helper (Tfh) cell differentiation in vivo. 
Tfh cells are a relatively new Th cell subset that 
plays a critical role in regulation of germinal 
centre (GC) responses in the spleen and for 
promoting B cell responses to antigen. The 
induction of Tfh cells is dependent on Bcl6 and 
the cytokine IL-21 [95-97]. Originally discov-
ered through an ENU mutagenesis screen in 
mice for autoimmune prone phenotypes, the 
Sanroque mutation is a hypomorphic allele 
caused by a point mutation in the conserved 
Roq domain leading to loss of function of the 
Roquin protein [61]. The Rch31san/san mice on a 
C57BL/6 genetic background develop a sys-
temic autoimmune Lupus-like disease that 
results in spontaneous GC formation in the 
spleen, increased numbers of Tfh cells, elevat-
ed levels of double stranded DNA antibodies 
and serum immunoglobulins that leads to the 
premature death of most Rch31san/san mice 
[61]. CD4+ Tfh cells in Rch31san/san mice consti-
tutively express high levels of inducible costim-
ulator (ICOS) at the cell surface of T cells and 
this phenotype is responsible for driving the 
spontaneous GC formation in the spleen of 
Sanroque mice [61]. Roquin plays a key role in 
regulating the expression of Icos mRNA in T 
cells by binding to the 3’ untranslated region 
targeting it for degradation [98]. The loss of 
function of Rc3h1 leads to increased stability 
of Icos mRNA CD4+ Tfh cells express constitu-
tively high levels of ICOS at the cell surface that 
allows them to interact with autoreactive B 
cells to promote autoimmune responses. 
Conclusion
The RING finger E3 ligases Cbl-b, Itch and Grail 
play multiple roles in attenuating the activation 
and differentiation of naïve T cells. The immune 
system places an important emphasis on 
restricting the activation of the IL-2 gene in 
naïve T cells to limit the inappropriate activa-
tion and proliferation of autoreactive T cell 
clones. Thus the E3 ligases are not only play 
key roles in attenuating TCR signaling, but they 
appear to have evolved important roles in 
directing iTreg cell differentiation as well. Thus 
the breakdown in anergy can not only unleash-
es TCR signaling in autoreactive T cell clones, 
but disables an immunoregulatory checkpoint 
that is normally controlled by iTreg cells.
The development of autoimmune diabetes is 
controlled by genetic and environmental fac-
tors that can lead to a breakdown in the immu-
noregulatory checkpoints that normally prevent 
activation of autoreactive T cells. As highlighted 
in this review there are multiple E3 ubiquitin 
ligases that are used to control the fate of naïve 
T cells. Some of these E3 ligases are crucial for 
dampening TCR signaling, but as highlighted by 
the function of Roquin, new mechanisms of 
controlling the activation and/or differentiation 
of autoreactive T cells could still emerge. 
Roquin is one of the first E3 ligases to be 
involved in controlling mRNA degradation of a 
key protein involved in costimulation of naïve T 
cells.
The diversity of E3 ligases involved in control-
ling autoimmunity to organ specific antigens 
such as in type 1 diabetes makes these pro-
teins potential targets for immune therapy. The 
link between Cbl-b, Itch and iTreg cell differen-
tiation is an exciting development. There is 
great excitement as to the role of iTregs in 
immune cell therapy for the treatment of auto-
immune diseases. As we come to a clear under-
standing of how to induce Foxp3 expression to 
direct iTreg cell differentiation, the use of Treg 
therapy may continue to flourish and provide an 
exciting opportunity to hopefully treat and cure 
type 1 diabetes in the future.
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